Other
68Ga-PSMA PET/CT
Total Trials
3
Max Phase
—
Type
DIAGNOSTIC TEST
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)
Phase Distribution
Ph phase_3
1
33%
Ph not_applicable
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Terminated(1)
Other(2)
Detailed Status
unknown1
Suspended1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (33.3%)
N/A2 (66.7%)
Trials by Status
unknown133%
suspended133%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
terminatednot_applicable
Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.
NCT03465579
suspendedphase_3
68Ga-PSMA PET/CT in Prostate Cancer
NCT04684628
unknownnot_applicable
A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer
NCT05073653
Clinical Trials (3)
Showing 3 of 3 trials
NCT03465579Not Applicable
Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.
NCT04684628Phase 3
68Ga-PSMA PET/CT in Prostate Cancer
NCT05073653Not Applicable
A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 3